Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for WHSC1/NSD2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WHSC1/NSD2 SET Domain / Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View WHSC1/NSD2 Products |
| Gene Delivery | WHSC1/NSD2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View WHSC1/NSD2 Products |
| Benchmark Ab | Anti-WHSC1/NSD2 (Sequence of Reference Clone) Recombinant positive control for Western / IP / ChIP. |
View WHSC1/NSD2 Products |
| Validator | WHSC1/NSD2 siRNA Set For knockdown verification and target engagement studies. |
View WHSC1/NSD2 Products |
| Related Target A | NSD3 / WHSC1L1 Closest paralog; essential for selectivity counter-screening. |
View NSD3 Products |
| Related Target B | NSD1 Paralog selectivity panel member; shared SET domain architecture. |
View NSD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| NSD paralog selectivity (NSD1 / NSD3 counter-screen) | WHSC1/NSD2, NSD1, and NSD3 recombinant proteins available with >95% purity; sequence verified by mass spectrometry. |
| Resistance mutation profiling | Custom mutant recombinant protein service; theoretical MW confirmed. |
| Lack of cellular target engagement controls | Pre-made lentivirus and validated siRNA for genetic modulation. |
| Assay false positives / off-target artifacts | Sequence-specific siRNA included for specificity checks. |
Live WHSC1/NSD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
"The race for WHSC1/NSD2 therapeutics is intensifying, with major players shifting focus from broad epigenetic inhibitors to highly selective catalytic and allosteric blockers. As first-generation small molecules enter the clinic, the next wave of R&D is targeting paralog-selective inhibitors and protein degradation strategies to overcome scaffolding function and resistance."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | AstraZeneca, Biomea Fusion, C4 Therapeutics | Multiple Myeloma, Acute Lymphoblastic Leukemia | Biochemical H3K36me2 assay (Need high-purity SET domain protein) |
| PROTAC / Degraders | C4 Therapeutics, Emerging Biotech | Refractory Myeloma, Solid Tumors | Cellular H3K36me2 modulation assay (Need lentivirus/siRNA controls) |
| Allosteric / Covalent Inhibitors | Biomea Fusion, Academic Institutes | Hematologic Malignancies | Selectivity Assay (Need NSD1/NSD3 paralog panel) |